Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma.

Goyal G, Rajkumar SV, Lacy MQ, Gertz MA, Buadi FK, Dispenzieri A, Hwa YL, Fonder AL, Hobbs MA, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kourelis TV, Warsame R, Kyle RA, Kumar SK.

Leukemia. 2019 Feb 20. doi: 10.1038/s41375-019-0419-7. [Epub ahead of print]

PMID:
30787429
2.

Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.

Magnano L, Fernández de Larrea C, Elena M, Cibeira MT, Tovar N, Aróstegui JI, Pedrosa F, Rosiñol L, Filella X, Yagüe J, Bladé J.

Clin Lymphoma Myeloma Leuk. 2016 Jun;16(6):e71-7. doi: 10.1016/j.clml.2016.02.034. Epub 2016 Feb 27.

PMID:
27013181
3.

The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.

Sigurdardottir EE, Turesson I, Lund SH, Lindqvist EK, Mailankody S, Korde N, Björkholm M, Landgren O, Kristinsson SY.

JAMA Oncol. 2015 May;1(2):168-74. doi: 10.1001/jamaoncol.2015.23.

PMID:
26181017
4.

Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.

Cesana C, Klersy C, Barbarano L, Nosari AM, Crugnola M, Pungolino E, Gargantini L, Granata S, Valentini M, Morra E.

J Clin Oncol. 2002 Mar 15;20(6):1625-34.

PMID:
11896113
6.

Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease.

Pineda-Roman M, Bolejack V, Arzoumanian V, Anaissie E, van Rhee F, Zangari M, Walker R, Hollmig K, Shaughnessy JD Jr, Epstein J, Krishna S, Crowley J, Barlogie B.

Br J Haematol. 2007 Feb;136(3):393-9. Epub 2006 Dec 8.

PMID:
17156398
7.

Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis.

Rajkumar SV, Mesa RA, Fonseca R, Schroeder G, Plevak MF, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Gertz MA, Kyle RA, Russell SJ, Greipp PR.

Clin Cancer Res. 2002 Jul;8(7):2210-6.

8.

A contribution to examination of propidium iodide and annexin V plasma cells indices in multiple myeloma.

Scudla V, Ordeltova M, Bacovsky J, Vytrasova M, Sumna E, Martinek A, Horak P.

Neoplasma. 2003;50(5):363-71.

PMID:
14628090
9.

Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.

van de Donk NW, Mutis T, Poddighe PJ, Lokhorst HM, Zweegman S.

Int J Lab Hematol. 2016 May;38 Suppl 1:110-22. doi: 10.1111/ijlh.12504. Epub 2016 May 9. Review.

PMID:
27161311
10.

The diagnostic value of SE MRI and DWI of the spine in patients with monoclonal gammopathy of undetermined significance, smouldering myeloma and multiple myeloma.

Dutoit JC, Vanderkerken MA, Anthonissen J, Dochy F, Verstraete KL.

Eur Radiol. 2014 Nov;24(11):2754-65. doi: 10.1007/s00330-014-3324-5. Epub 2014 Aug 9.

PMID:
25106487
11.

Asymptomatic and Treatment-requiring Multiple Myeloma - Data from the Czech Registry of Monoclonal Gammopathies.

Brozova L, Jarkovský J, Pour L, Minárik J, Jungová A, Gregora E, Spicka I, Maisnar V, Hájek R.

Klin Onkol. 2017 Summer;30(Supplementum2):51-59. doi: 10.14735/amko20172S51.

PMID:
28903571
12.

MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology.

Mateos MV, Landgren O.

Cancer Treat Res. 2016;169:3-12. Review.

PMID:
27696254
13.

Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell disorders.

Kumar SK, Dingli D, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, Rajkumar SV, Litzow MR, Gertz MA.

Br J Haematol. 2008 Apr;141(2):205-11. doi: 10.1111/j.1365-2141.2008.07069.x. Epub 2008 Mar 3.

PMID:
18318761
14.

Clinical characteristics and outcomes in biclonal gammopathies.

Mullikin TC, Rajkumar SV, Dispenzieri A, Buadi FK, Lacy MQ, Lin Y, Dingli D, Go RS, Hayman SR, Zeldenrust SR, Russell SJ, Lust JA, Leung N, Kapoor P, Kyle RA, Gertz MA, Kumar SK.

Am J Hematol. 2016 May;91(5):473-5. doi: 10.1002/ajh.24319. Epub 2016 Apr 6.

15.

Angiogenic cytokines profile in smoldering multiple myeloma: no difference compared to MGUS but altered compared to symptomatic myeloma.

Gkotzamanidou M, Christoulas D, Souliotis VL, Papatheodorou A, Dimopoulos MA, Terpos E.

Med Sci Monit. 2013 Dec 20;19:1188-94. doi: 10.12659/MSM.889752.

16.

Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis.

Go RS, Gundrum JD, Neuner JM.

Clin Lymphoma Myeloma Leuk. 2015 Mar;15(3):177-186.e4. doi: 10.1016/j.clml.2014.09.004. Epub 2014 Sep 28.

17.

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies.

Korde N, Kristinsson SY, Landgren O.

Blood. 2011 May 26;117(21):5573-81. doi: 10.1182/blood-2011-01-270140. Epub 2011 Mar 25. Review.

18.

Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies.

Landgren O.

Hematology Am Soc Hematol Educ Program. 2013;2013:478-87. doi: 10.1182/asheducation-2013.1.478. Review.

PMID:
24319222
19.

Obesity and the Transformation of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma: A Population-Based Cohort Study.

Chang SH, Luo S, Thomas TS, O'Brian KK, Colditz GA, Carlsson NP, Carson KR.

J Natl Cancer Inst. 2016 Dec 31;109(5). doi: 10.1093/jnci/djw264. Print 2017 May.

20.

Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus: a population-based retrospective cohort study.

Chang SH, Luo S, O'Brian KK, Thomas TS, Colditz GA, Carlsson NP, Carson KR.

Lancet Haematol. 2015 Jan;2(1):e30-6. Erratum in: Lancet Haematol. 2015 Feb;2(2):e54.

Supplemental Content

Support Center